Attorney: Glaxo Comes at Rescuing Hundreds of Avandia Suits

GlaxoSmithKline Plc. has been able to settle with almost 700 individuals, who say that they experienced harm, since they took the diabetes drug, Avandia, a lawyer involved with loads of the cases informed about it.

Philadelphia attorney, Sol Weiss of AnapolSchwartz Law Company stated that he had settled with the drug manufacturer for 189 people, and that the sum that Glaxo would reimburse was not to be disclosed.

There are 500 or even more that have been given the confirmation regarding making settlement with them.


GlaxoSmithKline Steps Up To Purchase Stakes in South Korea’s Pharmacy Company

GlaxoSmithKline came forth to drive into up-and-coming markets on Tuesday, by approving to purchase a 9.9 percent stake in South Korea's Dong-A Pharmaceuticals for 73.9 million pounds, which is approx. $114 million.

Up-and-coming markets are the new battlefield for the world's top drug manufacturers, as sales stall in Western markets.

Glaxo Chief Executive, Andrew Witty, has already signed a cord of contracts, so as to boost his company's marks in key emerging markets, that includes taking a similar minority asset in South African Aspen Pharmacare.


Rotavirus Vaccine Benefits Outweigh Risks

GlaxoSmithKline Plc and Merck & Co. Inc.’s rotavirus vaccine benefits outweigh any risk from recently discovered pig virus contamination, according to members of a US advisory panel Friday.

DNA bits from the porcine circovirus (PCV) have been detected in Glaxo’s Rotarix and Merck’s Rotateq, however, the US Food and Drug Administration (FDA) assured, there was no evidence that the virus harms people.


GSK reports 13% jump in 1Q sales

British pharmaceuticals giant GlaxoSmithKline has reported a better-than-expected increase of 13 per cent in first-quarter sales, helped by the strong demand for company's swine flu treatment drugs.

The company said that it pocketed £698 million from the sales of swine flu vaccine that pushed total sales to £7.4 billion.


GlaxoSmithKline Biologicals Declares H1N1 Vaccine Elicits High Immune Response in Infants

It has been reported that a single injection with one and a half dose of the human swine flu vaccine educed a towering immune reaction in 100% of the infants 21 days after they were vaccinated This was noticed during the first clinical trial of the epidemic vaccine in children.

It is believed that this can direct Canadian health officials towards changing their suggestions for flu shots in young children.



Subscribe to RSS - GlaxoSmithKline